Der skal udvises forsigtighed når patienter med portal hypertension, der har det godt og hvor behandlingen tolereres, skifter fra et chelaterende produkt til Wilzin,.
Caution should be exercised when switching patients with portal hypertension from a chelating agent to Wilzin, when such patients are doing well and the treatment is tolerated.